Eczema, Psoriasis, and Hidradenitis - Oh My!

Living with an inflammatory skin condition can be a challenge. However, recent advancements in medications are offering new hope for patients looking for safe and effective treatment options. 

Non-steroid Options for Eczema/Atopic Dermatitis 

People who suffer from eczema typically experience an itchy, red, and scaly rash. It can be treated with topical steroids or moisturizers, but Dr. Christopher Mancuso at Nashua Dermatology Associates of Southern New Hampshire Health says there are some new effective medications with different side effect profiles. “There are JAK inhibitor medications out there that don’t have the side effects typically associated with the use of steroids,” he explains. “You don’t have to worry about thinning of the skin or discoloration, like we do with some steroid creams.” 

In addition to creams, Dr. Mancuso says there are oral and injectable medications that are also effective in treating moderate to severe eczema. “Oral medications work really quickly. And with injectables, you only administer every couple of weeks. Some are even approved for ages 6 months and up so they’re incredibly safe medications with almost no side effects to mention.” 

New Medications for Hidradenitis 

Hidradenitis can be a very debilitating skin condition. It appears as large, painful lumps typically found in the armpits and groin area. Dr. Mancuso says it’s an underdiagnosed disease and until recently, there haven’t been a lot of medications available to treat it. “Some people have Hidradenitis for years and they just blame themselves, thinking there’s nothing they can do, but there is something you can do.”  

Injectable medications have shown promising results in treating Hidradenitis. Dr. Mancuso says there are some risks but it’s overall a great option for people with this condition. “Other than a slight increase in upper respiratory infections, most people don’t notice any side effects other than that their skin has cleared up.” These medications are taken once a month and can be a desirable alternative to topical or oral antibiotics. 

psoriasis.pngTargeted Treatments for Psoriasis 

Psoriasis is a buildup of skin cells that causes red, scaly, or itchy patches on the skin. Dr. Mancuso says 20% of people who suffer from skin psoriasis also get psoriatic arthritis, which causes painful swelling in the joints. Fortunately, there are new medications that can help. 

“Some of these new drugs are much less immune suppressing than some of the older medications, which means they’re getting better at targeting the actual cause of psoriasis rather than blocking an earlier pathway that has a lot of side effects downstream,” he explains. Dr. Mancuso says they’re safer, more effective, and the injectable medications are only administered every 2 or 3 months, which can be easier to manage for patients.  

Interested in Trying a New Treatment? 

In the ever-evolving landscape of dermatology, the introduction of new medications for inflammatory skin conditions such as eczema, psoriasis, and hidradenitis signifies a monumental shift towards more patient-friendly treatments. The development of non-steroid options, injectables, and targeted treatments not only expands the arsenal against stubborn skin diseases but also emphasizes a future where management and relief are not only possible but are accompanied by minimal side effects. For patients living with these conditions, the message is clear: innovative treatments are not just on the horizon—they're here, offering a new lease on life free from the constraints of chronic skin conditions. 

If you are looking to try a new treatment for your skin condition, call and book an appointment today.

Nashua Dermatology Associates
Hours: Monday-Friday | 7:15am - 5:00pm 
Phone: (603) 579-9648 
Address: 17 Prospect Street, Suite N301, Nashua, NH 03060
 

Mancuso,-Chris.jpgChristopher Mancuso, DO practices at Nashua Dermatology Associates. He is available for appointments at Pelham Medical Center on Mondays.





 

You may also enjoy: 


Posted: 3/26/2024